sEH inhibitor-20 is a metabolically stable, orally active sEH inhibitor with an IC50 of 0.2 nM. It exhibits significant analgesic and anti-inflammatory properties, making it a promising candidate for researching neuropathic pain.

sEH inhibitor-20 (Compound FP9) at a concentration of 0.1 μM for 1 hour exhibits remarkable metabolic stability (t ₁/₂ > 184 min) in both human and mouse liver microsomes, indicating resistance to rapid hepatic metabolism in vivo. At 10 μM for 16 hours, it demonstrates moderate brain permeability (Pe: 3.83 × 10⁻⁶ cm/s) in the PAMPA-BBB model. When pre-treated at 1-1000 nM for 0.5 hours and then treated for 6 hours in an LPS-induced PBMC inflammation model, sEH inhibitor-20 significantly reduces TNF-α and IL-6 levels without cytotoxic effects, maintaining cell viability even at 10 μM.

sEH inhibitor-20 (Compound FP9) (10, 30 mg/kg, p.o.) exhibits potent and long-lasting analgesic effects in a paclitaxel-induced neuropathic pain model and shows a low propensity for tolerance development.